MarketCap
Facebook
X
Telegram
Novavax Operating Cycle | NVAX
Annual Operating Cycle Novavax
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 85.6 | 154 | 112 | 58.7 | 114 | 103 | - | - | - | 29.7 | 23.4 | 126 | 120 | 42.7 | 94.5 | 28.7 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 154 | 23.4 | 84.1 |
Quarterly Operating Cycle Novavax
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 219 | 113 | 71.9 | - | 82 | - | - | - | 169 | 102 | 205 | - | 54.6 | 226 | 407 | - | 32 | 16.4 | 32.5 | - | 152 | 673 | 3.64 K | 77.6 | 273 | 204 | 85.9 | - | - | - | - | - | - | - | 1.87 | 6.96 | 13.5 | 14 | 29.5 | 36.2 | 32.4 | 15.1 | 45.4 | 102 | 83.4 | 83 | 57.6 | 19.9 | 36.3 | 49.4 | 34.8 | 20.2 | 16 | 13 | 29.2 | 30.7 | 35.8 | 59.8 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.64 K | 1.87 | 175 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
205 | $ 51.0 | 1.83 % | $ 1.48 B |  USA |
 |
Clovis Oncology
CLVS
|
271 | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
5.06 | - | - | $ 401 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
733 | $ 60.26 | 0.06 % | $ 11.6 B | USA |
 |
Genocea Biosciences
GNCA
|
24.9 | - | -15.0 % | $ 3.04 M | USA |
 |
Catalyst Biosciences
CBIO
|
293 | $ 13.99 | 0.84 % | $ 1.25 B | USA |
 |
C4 Therapeutics
CCCC
|
27.9 | $ 2.98 | 0.3 % | $ 247 M | USA |
 |
Codexis
CDXS
|
70.7 | $ 1.32 | 1.09 % | $ 115 M | USA |
 |
Cerus Corporation
CERS
|
47 | $ 2.62 | 0.38 % | $ 499 M | USA |
 |
G1 Therapeutics
GTHX
|
52.6 | - | - | $ 370 M | USA |
 |
Coherus BioSciences
CHRS
|
656 | $ 1.13 | 0.43 % | $ 132 M | USA |
 |
Celldex Therapeutics
CLDX
|
321 | $ 31.1 | 1.16 % | $ 2.07 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
233 | $ 4.25 | 3.16 % | $ 51.9 M |  Israel |
 |
AbbVie
ABBV
|
350 | $ 264.34 | 0.09 % | $ 468 B | USA |
 |
Humanigen
HGEN
|
598 | - | -81.12 % | $ 4.28 M | USA |
 |
Cocrystal Pharma
COCP
|
78.2 | $ 1.17 | 1.74 % | $ 13.2 M | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 12.7 | 0.4 % | $ 3.79 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
654 | $ 5.4 | 2.65 % | $ 286 M | USA |
 |
Collegium Pharmaceutical
COLL
|
572 | $ 22.53 | 0.2 % | $ 713 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
383 | $ 116.1 | 4.93 % | $ 12.1 B | USA |
 |
Фармсинтез
LIFE
|
9.78 | - | - | - |  Russia |
 |
Cardiff Oncology
CRDF
|
294 | $ 1.24 | 0.74 % | $ 82.9 M | USA |
 |
Karuna Therapeutics
KRTX
|
15.9 | - | - | $ 12.2 B | USA |
 |
Curis
CRIS
|
64.7 | $ 0.83 | 1.1 % | $ 10.9 M | USA |
 |
CorMedix
CRMD
|
439 | $ 7.85 | 1.03 % | $ 565 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
554 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.3 K | $ 54.23 | 0.23 % | $ 4.88 B |  Schweiz |
 |
Champions Oncology
CSBR
|
74.9 | $ 4.9 | 0.1 % | $ 67.8 M | USA |
 |
Chimerix
CMRX
|
52.5 | - | - | $ 756 M | USA |
 |
Cue Biopharma
CUE
|
43.1 | $ 31.41 | 1.45 % | $ 2.98 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
50 | $ 4.85 | 0.2 % | $ 929 M | Canada |
 |
Cytokinetics, Incorporated
CYTK
|
71.3 | $ 64.66 | 0.17 % | $ 7.77 M | USA |
 |
Adagene
ADAG
|
58.9 | $ 2.93 | 2.86 % | $ 173 M |  China |